Key Highlights

  • Fiscal Q2 non-GAAP EPS of $1.21 rose 26%, but full-year organic growth guidance was cut to 3.5%–4.5% from 4.5%–5.5%, profitability is improving faster than the Top Line .
  • The $271.6 million net charge sized and substantially settled the embryo culture media recall claims, removing an open-ended Liability at the cost of a GAAP loss quarter.
  • MiSight's clinical evidence is the strongest in the category, but Cooper discloses no MiSight Revenue , so its contribution to growth cannot be verified from filings.
  • Cooper's fiscal second quarter, covering the three months and reported on 4 June, was two stories filed under one headline.

A record quarter with a $271.6 million hole in it

Companies ( Nasdaq :COO). Cooper's fiscal second quarter, covering the three months and reported on 4 June, was two stories filed under one headline. Revenue reached $1.082 billion, up 8% reported and 5% organically, and non-GAAP Diluted Earnings per Share of $1.21 rose 26% year over year on a non-GAAP Operating Margin of 27%, up 260 basis points.

Underneath that, the company took a $271.6 million net pre-tax charge in selling, general and administrative expense, a $324.1 million accrued litigation liability offset by $52.5 million of expected insurance recoveries, to settle claims stemming from CooperSurgical's December 2023 recall of LifeGlobal embryo culture media. The charge flipped GAAP operating margin from 18% to negative 3% and produced a GAAP loss of $0.40 per share against a $0.44 profit a year earlier. Chief executive Al White framed the settlements as clearing the path "to move forward with our strategic review," the portfolio and structure examination announced at last closing that explicitly contemplates divestitures, joint ventures and Business combinations.

The quarter also carried a cut nobody advertised. Full-year organic growth guidance fell to 3.5%–4.5% from the 4.5%–5.5% given three months earlier, and the revenue range slipped to $4.285–$4.321 billion. Non-GAAP EPS guidance of $4.58–$4.66 was held.

The tape reads as de-rating, not shock

Shares closed at $72.32, off $0.33 or 0.45%, giving a Market Value near $14.1 billion. The 52-week range runs from $58.89 to $89.83, so the stock sits roughly 19% below its high and 23% above its low.

The earnings reaction itself was positive: COO jumped 8.58% to $67.34 on 5 June, the session after results, on relief that the recall liability had been sized. The weakness that matters happened earlier and over longer periods. Sixteen analysts tracked by data aggregators carry a "Buy" consensus and a $81.21 average target, an opinion, not evidence, but a measure of the gap between the sell side and the tape.

Two businesses that no longer grow alike

CooperVision, at $723.5 million in the quarter, is the larger half and grew 4% organically. The specialty end carried it: toric and multifocal lenses rose 7% organically to $364.9 million while spheres and other products managed 1% on $358.6 million. Geographically the split was stark, Americas up 7%, EMEA up 6%, Asia Pacific down 6%, a decline consistent with the 4% Asia Pacific fall in the prior quarter and pointing to sustained weakness rather than a timing quirk.

The surgical half delivered $358.0 million, up 6% organically, and it was fertility that led at $143.8 million and 10% organic growth. Office and surgical products, the division containing the PARAGARD copper IUD, grew 4% to $214.2 million. Cooper does not break out PARAGARD revenue, and its fiscal Q2 legal note identifies no PARAGARD litigation as a disclosed matter.

Competitor prints frame Cooper's position uncomfortably. In the June calendar quarter, Johnson & Johnson's Vision segment grew 5.6% operationally, with contact lenses and other up 6.0% to $1,025 million. Bausch + Lomb's Vision Care unit grew 4% in constant currency to $784 million. Alcon's contact lens line rose 4% in constant currency in its March quarter, helped by price. Cooper is growing with the market, not ahead of it.

Myopia control: strong science, invisible revenue

MiSight 1 day was the first soft contact lens with an FDA indication for slowing myopia progression in children, alongside correction of myopic ametropia, for patients aged 8 to 12 at initiation with refraction between -0.75 and -4.00 diopters. CooperVision's three-year trial data showed a 59% reduction in myopia progression and a 52% reduction in axial elongation versus a single-vision daily lens.

The commercial case rests on Annuity Economics : a child fitted at eight is a recurring daily-disposable customer for years, at premium pricing, inside a category where practitioners rather than retailers control the fit. Cooper is extending the Franchise into its silicone hydrogel platform, management cited "early traction from MyDay MiSight" among fiscal Q1 2026 launch drivers, and in May 2026 completed enrollment of more than 3,000 children across over 100 sites in the United States and China for MiSight post-approval studies, with data rolling out between 2027 and 2030.

The problem for investors is arithmetic. Cooper discloses no MiSight revenue line, no fitted-patient count and no myopia-management growth rate in its earnings release or 10-Q. On the disclosed evidence, myopia control is not yet a growth engine; it is an option whose size cannot be verified from company filings. Anyone modeling it is estimating.

The case for and against the discount

At $72.32 the shares sit at roughly 15.6 times the midpoint of management's own fiscal 2026 non-GAAP EPS guidance; aggregated market data puts forward earnings at 15.3 times, against Alcon at 18.2 and Bausch + Lomb at 17.2. The trailing multiple of 61 is meaningless, it capitalizes the litigation charge. Price to sales is 3.4, EV/EBITDA 19.1, and free Cash Flow Yield 4.0%.

The bull argument is that the discount reflects a resolved problem. Gross margin held at 68% while tariffs pressured costs, non-GAAP operating margin expanded, the recall liability now has a number attached, and the strategic review gives management an explicit mandate to separate Assets the market is not valuing. Debt of $2,460.2 million against $138.8 million of cash is manageable against a reaffirmed objective of more than $2.2 billion of free cash flow across fiscal 2026 to 2028, and 1.3 million shares were repurchased for $105.6 million in the first half.

The bear argument is that the discount reflects a growth problem. Organic guidance was cut mid-year, sphere lenses grew 1%, Asia Pacific is shrinking, and free cash flow of $96.4 million in the quarter, after $86.4 million of Capital Expenditure on $182.8 million of Operating Cash Flow , leaves limited firepower for Buybacks at this Leverage . A separate UK tax dispute over the 2014 Sauflon Acquisition went against Cooper at the First-tier Tribunal, with exposure of up to £71.7 million plus interest and no liability booked.

What decides it

The strategic review is now the dominant variable, and Cooper has said it will not comment until disclosure is "appropriate and necessary." Absent that, the September quarter has to show CooperVision reaccelerating and Asia Pacific stabilizing. Until MiSight gets its own line in the release, the myopia thesis stays a matter of faith rather than a matter of record.

Upcoming Catalysts

  • Fiscal Q3 2026 results, 4:15pm ET. Whether CooperVision organic growth reaccelerates and Asia Pacific stops declining, against reduced full-year guidance.
  • Strategic review conclusions, no date given. Announced and explicitly open to divestitures, joint ventures and mergers; a CooperSurgical separation is the outcome the valuation gap implies.
  • MiSight post-approval study readouts, 2027 through 2030. Enrollment of over 3,000 children completed May 2026 across US and China sites.
  • UK First-tier Tribunal appeal. A loss would crystallize up to £71.7 million plus interest, currently unaccrued.
  • Fiscal 2027 guidance, expected with Q4 results in December 2026. The first clean read on growth after the recall charge clears.

Principal Risks

  • Growth deceleration in the core lens business. Sphere and other products grew 1% organically and Asia Pacific fell 6% in fiscal Q2; competitors are matching or beating Cooper's growth rate.
  • Residual recall exposure. More than 1,500 claimants and over 140 lawsuits, including three uncertified putative class actions, were outstanding; "substantially all" is not all, and insurance recoveries of $52.5 million are estimates.
  • Leverage limits flexibility. Total debt of $2,460.2 million against $138.8 million of cash, with $550 million of term loans due December 2026 and a revolver drawn at a 4.66% weighted-average rate.
  • Tariffs and currency. Management said positive FX offset higher costs including tariffs in fiscal Q2; the offset is not guaranteed to persist, and Alcon has guided to a $100–$150 million net Tariff impact for 2026 as a sector marker.
  • Strategic review disappointment. If the review concludes without structural change, the discount to Alcon and Bausch + Lomb loses its most obvious catalyst.

Conclusion

Fiscal Q2 non-GAAP EPS of $1.21 rose 26%, but full-year organic growth guidance was cut to 3.5%–4.5% from 4.5%–5.5%, profitability is improving faster than the top line. Set against that: Sphere and other products grew 1% organically and Asia Pacific fell 6% in fiscal Q2; competitors are matching or beating Cooper's growth rate. The next real test: Fiscal Q3 2026 results, 4:15pm ET. Whether CooperVision organic growth reaccelerates and Asia Pacific stops declining, against reduced full-year guidance.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.